1. Home
  2. BCDA vs WRNT Comparison

BCDA vs WRNT Comparison

Compare BCDA & WRNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • WRNT
  • Stock Information
  • Founded
  • BCDA N/A
  • WRNT 2013
  • Country
  • BCDA United States
  • WRNT Japan
  • Employees
  • BCDA N/A
  • WRNT N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • WRNT
  • Sector
  • BCDA Health Care
  • WRNT
  • Exchange
  • BCDA Nasdaq
  • WRNT Nasdaq
  • Market Cap
  • BCDA 9.4M
  • WRNT 7.4M
  • IPO Year
  • BCDA N/A
  • WRNT 2023
  • Fundamental
  • Price
  • BCDA $2.95
  • WRNT $0.32
  • Analyst Decision
  • BCDA Strong Buy
  • WRNT
  • Analyst Count
  • BCDA 1
  • WRNT 0
  • Target Price
  • BCDA $60.00
  • WRNT N/A
  • AVG Volume (30 Days)
  • BCDA 86.1K
  • WRNT 31.4K
  • Earning Date
  • BCDA 08-07-2024
  • WRNT 08-15-2024
  • Dividend Yield
  • BCDA N/A
  • WRNT N/A
  • EPS Growth
  • BCDA N/A
  • WRNT N/A
  • EPS
  • BCDA N/A
  • WRNT 0.01
  • Revenue
  • BCDA $468,000.00
  • WRNT $1,554,761.00
  • Revenue This Year
  • BCDA N/A
  • WRNT N/A
  • Revenue Next Year
  • BCDA $436.41
  • WRNT N/A
  • P/E Ratio
  • BCDA N/A
  • WRNT N/A
  • Revenue Growth
  • BCDA N/A
  • WRNT 321.71
  • 52 Week Low
  • BCDA $2.62
  • WRNT $0.25
  • 52 Week High
  • BCDA $35.40
  • WRNT $5.85
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 37.81
  • WRNT 52.71
  • Support Level
  • BCDA $2.84
  • WRNT $0.26
  • Resistance Level
  • BCDA $3.66
  • WRNT $0.33
  • Average True Range (ATR)
  • BCDA 0.32
  • WRNT 0.03
  • MACD
  • BCDA 0.09
  • WRNT 0.00
  • Stochastic Oscillator
  • BCDA 17.44
  • WRNT 74.18

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About WRNT Warrantee Inc.

Warrantee Inc provides safety and security to all people around the world and realize a sustainable society through services such as free insurance model and free health care that make full use of unique technology.

Share on Social Networks: